The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease

Ho, Sing Kong; Wu, Yen Wen; Tseng, Wei Kung; Leu, Hsin Bang; Yin, Wei Hsian; Lin, Tsung-Hsien; Chang, Kuan Cheng; Wang, Ji Hung; Yeh, Hung I.; Wu, Chin-Pyng; Chen, Jaw Wen

doi:10.1038/s41598-018-32210-x

Cited by 21 publications

(18 citation statements)

References 33 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Held et al found that interleukin 6, an inflammation biomarker, was independently associated with the risk of major adverse cardiac events, CV death and all-cause mortality, while hsCRP was not significantly associated with major adverse cardiac events, CV death or cancer death 8 . In our latest publication, we reported the prognostic significance of H-FABP in patients with SCHD after 24 months of follow-up 24 . The Kaplan-Meier curves of the two groups (H-FABP ≥ 4.226 ng/mL and <4.226 ng/mL) were more significantly separated from 24 months to 36 months (Fig.…”

Section: Discussionmentioning

confidence: 99%

Potential impacts of high-sensitivity creatine kinase-MB on long-term clinical outcomes in patients with stable coronary heart disease

Tseng

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

chau-chung Wu 13,14,16* & Jaw-Wen chen 6,7,16* this study aimed to investigate the prognostic value of high-sensitivity creatine kinase-myocardial band or fraction (hsCK-MB) in comparison with other well-established biomarkers including heart type-fatty acid binding protein (H-FABP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with stable coronary heart disease (SCHD). A total of 1,785 patients were enrolled and followed for 36 months. The primary outcome was all-cause mortality. The secondary outcomes included cardiovascular (CV) death, acute myocardial infarction (AMI), angina-related hospitalizations, and hospitalizations for heart failure. The all-cause mortality rate was significantly higher in the high hsCK-MB group compared to the low hsCK-MB group (4.64% vs. 1.88%, p = 0.0026). After adjusting for baseline covariates, there were no significant differences for the secondary outcomes. H-FABP (≥4.226 ng/mL) was the best predictor for all-cause mortality (HR = 2.68, 95% CI = 1.28-5.62, p = 0.009) and cV death (HR = 6.84, 95% CI = 1.89-22.14, p = 0.003). The high NT-proBNP group had a higher AMIrelated hospitalization rate (HR = 1.91, 95% CI = 1.00-3.65, p = 0.05). Neither the addition of hsCK-MB to any other markers nor combinations of the three markers improved the prognostic significance of CV outcomes. In conclusion, hsCK-MB was an independent predictor for all-cause mortality but not CV outcomes in patients with SCHD. Combination of hsCK-MB, H-FABP and NT-proBNP failed to improve the prognostic power for all-cause mortality or CV outcomes. In 2018, the World Health Organization reported that 17.9 million people die each year, an estimated 31% of all deaths worldwide, from cardiovascular diseases including coronary artery disease, cerebrovascular disease, rheumatic heart disease and other conditions. Furthermore, 85% of all cardiovascular deaths are due to heart attack and stroke, and 60% of cardiovascular deaths occur in low-income and middle-income countries. Diabetes mellitus, hypertension, dyslipidemia, tobacco use, physical inactivity and family history of premature coronary

show abstract

Section: Discussionmentioning

confidence: 99%

Potential impacts of high-sensitivity creatine kinase-MB on long-term clinical outcomes in patients with stable coronary heart disease

Tseng

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another study cited H-FABP as an independent predictor for CV outcomes in patients with stable coronary heart disease (SCHD), mainly in CV death and acute heart failure-related hospitalizations. [ 23 ]…”

Section: Discussionmentioning

confidence: 99%

H-FABP: A beacon of hope for prediabetic heart disease

Ramesh

Chauhan

Goyal

et al. 2020

J Family Med Prim Care

View full text Add to dashboard Cite

Background: Prediabetes is increasingly being studied in the context of its association with cardiovascular disease (CVD). Besides raised HbA1c and sugar levels, the major underlying defect seems to be insulin resistance (IR). Subclinical atherosclerosis, measured by high sensitivity C reactive protein (hsCRP) and carotid artery intima media thickness (CIMT) underlies the pathogenesis of CVD in prediabetes. Heart-type fatty acid binding protein (H-FABP), a novel cardiac biomarker also might have a role in predictin prediabetic heart disease. Aims: The aim of the study is to compare serum levels of H-FABP in prediabetics and controls and correlate them with the atherosclerotic markers, hsCRP and CIMT. Setting and Design: 50 prediabetic patients and 50 age, sex and BMI matched controls were employed in the case control study. Serum F & PPBS, (HbA1c), fasting insulin levels were measured in cases and controls. Serum H-FABP was measured in both cases and controls. All cases and controls were subjected to bilateral CIMT measurements and Serum hsCRP levels. The values were compared between both the groups and subjected to appropriate statistical analysis. Statistical Analysis Used: Categorical variables were presented in number and percentage (%) and continuous variables were presented as mean ± SD and median. Normality of data was tested by Kolmogorov-Smirnov test. If the normality was rejected then non parametric test was used. Quantitative variables were compared using Independent t test/Mann-Whitney Test (when the data sets were not normally distributed) between the two groups. Qualitative variables were correlated using Chi-Square test/Fisher's Exact test. Spearman rank correlation coefficient was used to find out the correlation of various parameters with each other. Univariate linear regression was used to find out the cause and effect relationship between various parameters. A p <0.05 was considered statistically significant. The data analysis was done using Statistical Package for Social Sciences (SPSS) version 21.0. Results: The mean serum levels of H-FABP among cases and controls were 6.38± 2.76ng/ml and 3.24 ± 2.47 ng/ml respectively ( p <0.0001). Mean CIMT was found to be higher in prediabetics (0.59 ± 0.11 mm ) compared to controls (0.45 ± 0.07mm) ( p <0.0001). Serum hsCRP levels were also statistically higher in prediabetics (5.75± 4.16 mg/l) then that of controls (1.86± 1.67 mg/l) ( p <0.0001). The correlations of the two variables, hsCRP and CIMT with H-FABP were both strongly positive ( r = 0.687) & ( r = 0.779) respectively [both cases ( p < 0.0001)]. Conclusion: The novel cardiac biomarker H-FAPB might be a good predictor of cardiovascular risks in prediab...

show abstract

“…Various authors have investigated the role of H-FABP in patients suffering from HF with different methods over the last few years. Many studies postulate the independent relationship between H-FABP and outcome, as well as the risk of adverse CV events [40,[58][59][60][61]. In a recent study by Ho et al, for example, high levels of H-FABP were an independent risk factor for CV death and acute HF-related hospitalization in 1071 patients with chronic coronary disease [40].…”

Section: H-fabp As a Biomarker In Heart Failurementioning

confidence: 99%

“…Many studies postulate the independent relationship between H-FABP and outcome, as well as the risk of adverse CV events [40,[58][59][60][61]. In a recent study by Ho et al, for example, high levels of H-FABP were an independent risk factor for CV death and acute HF-related hospitalization in 1071 patients with chronic coronary disease [40]. In an interesting study from 2005 with 186 patients, Niizeki et al demonstrated superiority of the combined analysis of BNP and H-FABP for risk stratification in patients with CHF.…”

Section: H-fabp As a Biomarker In Heart Failurementioning

confidence: 99%

“…Regarding laboratory testing, different types of assays are frequently used in research and clinical settings for the detection and quantification of H-FABP in serum, plasma, or whole blood. These assays comprise enzyme-linked immunosorbent assays (ELISA) [6,15,[35][36][37], immunoturbidimetric assays [38,39], multiplex assays [40,41], and immunochromatographic assays [42,43]. Test times depend on the type of assay, and vary between 5 and 120 minutes (as reviewed in [44]).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Heart-Type Fatty Acid-Binding Protein (H-FABP) and Its Role as a Biomarker in Heart Failure: What Do We Know So Far?

Rezar

Jirak

Gschwandtner

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Heart failure (HF) remains one of the leading causes of death to date despite extensive research funding. Various studies are conducted every year in an attempt to improve diagnostic accuracy and therapy monitoring. The small cytoplasmic heart-type fatty acid-binding protein (H-FABP) has been studied in a variety of disease entities. Here, we provide a review of the available literature on H-FABP and its possible applications in HF. Methods: Literature research using PubMed Central was conducted. To select possible studies for inclusion, the authors screened all available studies by title and, if suitable, by abstract. Relevant manuscripts were read in full text. Results: In total, 23 studies regarding H-FABP in HF were included in this review. Conclusion: While, algorithms already exist in the area of risk stratification for acute pulmonary embolism, there is still no consensus for the routine use of H-FABP in daily clinical practice in HF. At present, the strongest evidence exists for risk evaluation of adverse cardiac events. Other future applications of H-FABP may include early detection of ischemia, worsening of renal failure, and long-term treatment planning.

show abstract

The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease

Cited by 21 publications

References 33 publications

Potential impacts of high-sensitivity creatine kinase-MB on long-term clinical outcomes in patients with stable coronary heart disease

Potential impacts of high-sensitivity creatine kinase-MB on long-term clinical outcomes in patients with stable coronary heart disease

H-FABP: A beacon of hope for prediabetic heart disease

Heart-Type Fatty Acid-Binding Protein (H-FABP) and Its Role as a Biomarker in Heart Failure: What Do We Know So Far?

Contact Info

Product

Resources

About